Biogen

Corporate venture investing at Biogen is conducted through Biogen New Ventures, led by Chelsea Johnson as Head of Biogen New Ventures. She reports within the corporate development structure, which ultimately falls under CEO Christopher Viehbacher. The unit operates with a mandate to make strategic minority equity investments aligned with the parent company's R&D priorities.

Deal flow comes primarily through the parent company's scientific networks, academic collaborations, and the dense biotech cluster in Cambridge and Boston. Biogen's internal research and development teams identify promising external science that could complement pipeline programs, with New Ventures providing the equity-investment mechanism to formalize those relationships. The firm also leverages conference and peer-review networks in the neurology space.

Biogen New Ventures makes direct minority equity investments rather than participating as a limited partner in external venture funds. The unit's purpose — gaining visibility into adjacent science and securing future partnering or acquisition optionality — is best served by direct stakes. There is no public record of the firm acting as an LP in biotechnology venture capital funds.

The venture unit concentrates on seed, Series A, and Series B investments in biotechnology companies that are past the pure academic-discovery stage but still pre-commercial. Deal disclosures typically fall in the single-digit to low-tens-of-millions range as part of larger syndicated rounds. Biogen does not operate a public-market or crossover investing arm.

Investments cluster around the parent company's strategic interests: multiple sclerosis, Alzheimer's disease and neurodegeneration, neuromuscular disease, neuropsychiatry, and immunology. Rare genetic diseases of the central nervous system form a secondary focus. The firm explicitly avoids oncology, metabolic disease, and cardiovascular biotechnology, where it has no pipeline programs.

Biogen New Ventures sits within the broader corporate development function and draws its capital allocation from the parent company's balance sheet, not from a ring-fenced venture fund. The parent spent roughly $2.2 billion on research and development in 2022 (per company filings), and venture equity investments represent a small fraction of that total, functioning as an external-innovation supplement rather than an independent return-seeking pool.

Yes. The Biogen Foundation was established in 2002 and operates as a separate 501(c)(3) entity from the corporate venture arm. It focuses on access to science education, health equity, and community resilience, particularly in the Boston area where the company is headquartered. Funding comes from parent-company grants and has no overlap with the New Ventures investment mandate.